« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Print This Page

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 48

ARISTOTLE: Efficacy Outcomes

This Figure is similar to Figure 38, with rivaroxaban, showing the results for the components of the primary outcomes of stroke or systemic embolism. As with the other factor Xa inhibitor, rivaroxaban, there was a reduction in hemorrhagic stroke compared to warfarin, but no reduction in ischemic stroke. Why this was so is unclear, but it is important for physicians to note that for both factor Xa inhibitors, ischemic stroke is reduced to the same extent as with warfarin – and warfarin is considered to have a good efficacy profile in this setting.

Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[99] Granger CB, Alexander JH, McMurray JV, et al; the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.